本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Enhanced DeepL glossary functionality – including new glossary generator, expanded language support and more – will boost global business translations, saving time, effort, and costs COLOGNE, Germany, Sept. 23, 2024 /PRNewswire/ -- DeepL, a leading global Language AI company, today announced several updates to its glossary feature, which is a powerful tool that enhances translation consistency and accuracy by enabling professionals and companies to personalize translations for specific terms. The tool now offers the industry's first smart glossary generator, which helps simplify and speed up the process of creating glossaries for translations. Glossary is also available in several new languages and within DeepL's browser extensions and integrations, fitting seamlessly into existing workflows to offer an even more accessible and smooth user experience across the web and applications like Google Workspace and Microsoft 365. "AI-powered translations are essential for businesses looking to overcome language barriers in today's increasingly connected world, and DeepL's powerful glossary tool takes this a step further by ensuring translations are personalized to a company's unique phrases and needs," said Christopher Osborne, VP of Product, DeepL. "We're always looking for ways to improve the DeepL experience and drive even more value and ROI for 100,000+ customers worldwide, and these new capabilities make our glossary even more efficient, accessible and user-friendly – empowering teams to achieve the customization and consistency they are looking for, while minimising time spent on costly alternatives like manual translations or find-and-replace tools." For global businesses aiming to drive revenue growth, investing in brand consistency across all communications and languages is essential to ensure that every message—whether technical terminology, product names, or branded terms—resonates clearly with teams, customers, and markets worldwide. Consistent branding has been proven to increase revenue by 20% or more[1] and enhance visibility by 3 to 4 times[2] – however, maintaining this consistency can be expensive and complex. DeepL's glossary tool simplifies this process, helping businesses and professionals easily create and scale high-quality, consistent multilingual communications across teams. With glossary, companies can create and manage custom translation glossaries to ensure that specific words or phrases are translated consistently according to their unique terminology. DeepL's glossary now offers the following expanded capabilities: The industry's first smart, AI-powered glossary generator: DeepL's new glossary generator is a first-of-its-kind tool enabling teams to create custom translation glossaries with a simple file upload. Previously translated files can be leveraged to generate entries for personalized DeepL glossaries, reducing the need for manual work and significantly enhancing efficiency, enabling teams to facilitate more consistent communication at scale. Expanded glossary language functionality: Glossary now supports Korean, Danish, Swedish, Norwegian, and Romanian translations, bringing the total number of languages to 16. This allows for more precise and nuanced translations across a wider range of linguistic contexts, helping businesses reach a broader audience. More convenient access across DeepL platforms: Users are now able to access and apply the glossary directly within the DeepL browser extensions for Chrome and Edge, enabling consistent translations across the web, including Google Workspace applications. Furthermore, the glossary can now also be applied directly within DeepL for Microsoft 365 integrations, including Word, Outlook, and PowerPoint. Additionally, the glossary can be accessed through DeepL's web browser, desktop apps, and API. Unlike other find-and-replace tools, DeepL's glossary excels with its advanced contextual understanding and ability to process complex grammatical elements—such as case, gender, and tense—to deliver nuanced, natural-sounding translations. This results in substantial productivity gains, largely due to the time saved in post-editing. Blind tests with language experts show that DeepL reduces post-editing time by 30% compared to Google Translate and 20% compared to Chat GPT-4. Furthermore, DeepL requires significantly fewer edits, with Google Translate and Chat GPT-4 needing two to three times as many feedback rounds. Glossary with DeepL Pro also offers enhanced data security, including proprietary data centers, the highest level of certification and compliance standards (ISO 27001 certification, GDPR/SOC 2 type 2 compliance), data encryption, and a commitment to never using Pro customer data to train models. DeepL's glossary generator is now available to Pro Advanced and Ultimate subscribers with support for TMX/DOCX/PDF files. It is initially available for glossaries in German, Spanish, Japanese, Italian, French, and Russian (to and from English), with more languages coming soon. Learn more about DeepL Pro and try out glossary yourself here. About DeepL DeepL is on a mission to break down language barriers for businesses everywhere. Over 100,000 businesses and governments and millions of individuals in 228 global markets trust DeepL's Language AI platform for human-like translation and better writing. Designed with enterprise security in mind, companies around the world leverage DeepL's AI solutions that are specifically tuned for language to transform business communications, expand markets, and improve productivity. Founded in 2017 by CEO Jaroslaw (Jarek) Kutylowski, DeepL today has over 900 passionate employees and is supported by world-renowned investors including Benchmark, IVP, and Index Ventures. [1] Marq, "2021 Brand Consistency Report" [2] Demand Metric x Lucid Press, "Impact of Brand Consistency" Report, 2016
Global Cloud Leader Collaborates with NVIDIA, XPENG, miHoYo, Atlas, Codium, UNESCO-ICHEI to Drive the Future of Mobility, Gaming, Travel, IT and Education HANGZHOU, CHINA - Media OutReach Newswire - 20 September 2024 - Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, today announced at its annual flagship event Apsara Conference that its proprietary foundational model Tongyi has attracted over 300,000 customers via its generative AI platform, Model Studio, a significant jump from 90,000 revealed in May. Leveraging Alibaba Cloud's Tongyi large models and its scalable global cloud infrastructure, businesses across automobile, gaming, travel, IT sectors have delivered enhanced customer experience and developed innovative solutions. Alibaba Cloud also unveiled a partnership with the International Centre for Higher Education Innovation under the auspices of UNESCO (UNESCO-ICHEI) to bring the benefits of generative AI to higher education institutes through digital training initiatives. "Our collaborations with industry-leading organizations demonstrate our dedication to delivering enhanced customer experiences and boosting enterprise efficiency through innovative solutions. Together with our partners, we want to empower more businesses and individuals to unlock the potential of generative AI through digital training and accessible cloud solutions," said Jingren Zhou, CTO of Alibaba Cloud. Driving the Future of Mobility and Smart Cockpits with LLMs Built on NVIDIA Alibaba Cloud today unveiled its large multimodal model (LMM) solution designed for automotive applications and co-developed with NVIDIA and Banma, Alibaba's intelligent cockpit solution provider. This solution, which will be made available to China-based automakers, aims to deliver a more interactive experience for car owners and redefine the smart mobility journey. Through this collaboration, Alibaba Cloud's portfolio of proprietary large language model Qwen—including the Qwen2-7B language model and the Qwen2-VL vision language model—have been seamlessly integrated with the NVIDIA DRIVE AGX Orin™ platform for autonomous vehicles. Additionally, NVIDIA's model acceleration technology has significantly reduced computational costs and minimized latency in Alibaba Cloud models' real-time processing of complex tasks. This ensures a smooth and uninterrupted intelligent experience for both drivers and passengers. This initiative marks the first integration of Alibaba's large models into NVIDIA's automotive platform. Leveraging Qwen's advanced capabilities in handling complex inquiries and processing visual intelligence, in-car voice assistants will be able to engage in dynamic, multi-turn conversations and even offer recommendations, ranging from providing information about nearby landmarks to proactively suggesting car headlights be turned on during snowy conditions. As part of the LMM solution, Alibaba Cloud's Mobile Agent—a multimodal AI agent for edge devices—will expand the capabilities of in-car voice assistants. Utilizing the Mobile Agent's strengths in complex task planning, self-reflection, and decision-making, users will be able to effortlessly execute voice commands, such as ordering milkshakes through a food delivery app, resulting in richer and more enjoyable in-car experiences. Looking ahead, Alibaba Cloud plans to work with NVIDIA to adapt Qwen models on NVIDIA DRIVE Thor, NVIDIA's next-generation centralized car compute platform that combines advanced driver assistance, autonomous driving, and AI cockpit capabilities into a single safe and secure system. Partnering with XPENG to Enhance Smart Cockpit Experience XPENG, a leading Chinese smart electric vehicle company, is leveraging Alibaba Cloud's AI models and robust cloud computing capabilities to redefine its smart cockpit and autonomous driving experience. It has tapped into Alibaba Cloud's Qwen to enhance its AI voice assistant, Xiao P, for a more superior smart cockpit experience. With no specific instructions needed, the LLM-enabled voice assistant excels at understanding complex conversational contexts and user intentions. It can engage in natural and intuitive dialogues with both drivers and passengers. For instance, when a user simply states, "It's cold inside the car," the voice assistant automatically adjusts the vehicle's temperature. In addition to utilizing Qwen for the smart cockpit, XPENG is collaborating with Alibaba Cloud to integrate large models for various innovations. Users can design custom stickers for their car's exterior through Alibaba Cloud's text-to-image model, Tongyi Wanxiang, within XPENG's mobile app. XPENG is also exploring the use of Alibaba Cloud's Tongyi Lingma, an AI coding assistant powered by Qwen, to enhance R&D efficiency in the latest automotive technologies. Alibaba Cloud also offers robust and resilient computing resources to help XPENG accelerate its training of large model for autonomous driving. Powering Immersive and Scalable Gaming Experience for miHoYo As a long-term partner, Alibaba Cloud has provided its cloud infrastructure support for miHoYo in launching its latest game Zenless Zone Zero, a new urban fantasy action role-playing game (ARPG) which received nearly 50 million pre-beta registrations, posting high demands on system stability and smooth access to the games' reservation website. With Alibaba Cloud's infrastructure and comprehensive product suite, Zenless Zone Zero has successfully addressed challenges in high server load, large volume of game data processing, and strong demand on platform stability, providing a smooth experience for players who logged in simultaneously on the day of its grand launch on July 4. The game has reached 50 million downloads within the first week since launched. Building A Strong Digital Foundation for Southeast Asia Atlas, an innovative B2B travel technology provider in Singapore, has leveraged Alibaba Cloud's infrastructure, machine learning and AI architecture innovations to serve over 50 global travel sellers and 150 low-cost airlines around the world. Alibaba Cloud's LLM Qwen and Model Studio platform also support Atlas' digital chatbot, providing customer support around the clock, addressing partner inquiries regarding booking procedures and payment options. Since collaborating with Alibaba Cloud in 2021, Atlas has reduced operational expenses by 45%. Alibaba Cloud has aided Atlas in transitioning from a startup in Singapore to becoming one of the leading industry players, revolutionizing the low-cost flight industry with its innovative travel platform. Additionally, Codium, a prominent software company in Thailand specializing in digital workplace solutions, has partnered with Alibaba Cloud to utilize its scalable cloud infrastructure and reliable solutions. The partnership aims to establish a strong digital foundation for businesses in Thailand and improve the Thai cloud market ecosystem by offering accessible cloud services and providing comprehensive local support and expertise to Thai clients. Empowering the Future of Education with UNESCO During Apsara Conference 2024, Alibaba Cloud signed a Memorandum of Understanding (MoU) with UNESCO-ICHEI to launch the GenAI and Cloud Micro-Certification online program for global learners. The program targets educators and students in higher education institutes including universities and colleges across Asia and Africa. The program, featuring 6 courses, is designed to deliver the fundamental knowledge and applications of generative AI and cloud computing technologies with easily understandable graphics and best practices of integrating generative AI into teaching activities to make learning more engaging, personalized, and efficient. After completing each course session, educators and students can take an exam to obtain a micro certification jointly issued by both UNESCO-ICHEI and Alibaba Cloud. With the gradual rollout of the program, the initiative aims to benefit around 12,000 educators and students globally by the end of 2025. Hashtag: #AlibabaCloudThe issuer is solely responsible for the content of this announcement.About Alibaba CloudEstablished in 2009, Alibaba Cloud (www.alibabacloud.com) is the digital technology and intelligence backbone of Alibaba Group. It offers a complete suite of cloud services to customers worldwide, including elastic computing, database, storage, network virtualization services, large-scale computing, security, big data analytics, machine learning and artificial intelligence (AI) services. Alibaba has been named the leading IaaS provider in Asia Pacific by revenue in U.S. dollars since 2018, according to Gartner. It has also maintained its position as one of the world's leading public cloud IaaS service providers since 2018, according to IDC.
ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing. Preliminary results from this 12-week study demonstrated that ISM001-055 possesses a favorable safety profile and dose-dependent response in lung function in patients with IPF. ISM001-055's positive Phase IIa results represent a proof-of-concept success for AI-driven drug discovery. CAMBRIDGE, Mass., Sept. 18, 2024 /PRNewswire/ -- Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055. ISM001-055 is a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary fibrosis (IPF). The study met both its primary endpoint of safety and its secondary efficacy endpoints, demonstrating dose-dependent response in forced vital capacity (FVC), a critical measure of lung function in IPF patients. Insilico's proprietary AI platform facilitated ISM001-055's target identification and molecular design. Its development was recently described in a March 2024 Nature Biotechnology paper, which detailed TNIK's identification as a novel therapeutic target in IPF and ISM001-055 subsequent design. This comprehensive paper showcased ISM001-055's preclinical evaluation and positive Phase 0 & Phase I clinical studies justifying this intervention's potential as a disease-modifying agent for IPF. ISM001-055's Phase IIa study(NCT05938920) was a randomized, double-blind, placebo-controlled trial that enrolled 71 patients with IPF across 21 sites in China. Patients were randomized to receive either placebo, 30mg once daily (QD), 30mg twice daily (BID), or 60mg QD for 12 weeks. Patient enrollment was initiated in April 2023, and the last subject's follow-up visit was completed in August 2024. A parallel Phase IIa(NCT05975983) clinical trial in the U.S. is ongoing and actively enrolling patients. In this 12-week Phase IIa study, ISM001-055 met its primary endpoint of safety and tolerability across all dose levels. Positive results were also reported for the secondary efficacy endpoint, wherein a dose-dependent FVC improvement was observed. Patients receiving 60mg QD of ISM001-055 demonstrated the largest improvement in FVC. Complete topline data will be released at the upcoming medical conference and clinical trial results will be submitted for publication in a peer-reviewed journal. "These results are very encouraging, particularly the dose-dependent response in FVC. IPF is a devastating disease, and seeing improvements in lung function over just 12 weeks of treatment is a promising indication that ISM001-055 may provide a new therapeutic option for patients. Our Phase IIa in the U.S. is actively recruiting patients," said Toby M. Maher, MD, PhD, a leading expert in interstitial lung disease and an investigator in the trial. "Last year, I presented a lecture on how generative AI can help with end-to-end drug discovery from disease modeling and target identification to generation of novel drugs with the desired properties and purposing it to a specific disease. I used Insilico's TRAF2 and NCK-interacting kinase (TNIK) inhibitor as a case study going from 0 to Phase I. The fact that this same drug demonstrated efficacy in addition to safety in a Phase IIa study is extraordinary and represents a true first in this new era of AI-powered drug discovery," said Michael Levitt, PhD, 2013 Nobel Laureate in Chemistry. "With all the hype that surrounds the potential of generative AI in drug discovery and many other potential applications, it is thrilling see to the dose dependence of ISM001-055 in Insilico Medicine's phase IIa IPF clinical trial. This is strong evidence that the drug is truly effective and that favorable results will continue to be seen in future trials," said Charles Cantor, PhD, a renowned geneticist and advisor to the company since 2014. "This is great news for the field of AI for drug discovery. The fact that this molecule is safe and has a dose-dependent response means that there is a green light for further studies. I am hopeful it continues its path to making a difference," said Alan Aspuru-Guzik, PhD, Professor of Chemistry and Computer Science at the University of Toronto and CIFAR AI Chair at the Vector Institute. "This study result represents a critical milestone in AI-powered drug discovery and in my life to date," said Alex Zhavoronkov, PhD, co-CEO of Insilico Medicine. "While we expected the drug to be safe, we did not expect to see such a clear dose-dependent efficacy signal after such a short dosing period. IPF is a very diverse disease and it is very rare to see improvement in FVC. With our novel TNIK inhibitor, we attempted to go after what we think is a common mechanism in fibrotic diseases and in aging to maximize indication expansion potential." "I am excited to see that ISM001-055 demonstrated obvious clinical efficacy in IPF patients in only 3-months treatment. While preliminary, this clinical data is certainly encouraging, and provides the clinical validation of AI-powered drug R&D for both novel target and novel molecule," said Feng Ren, PhD, co-CEO and CSO of Insilico Medicine. " This is a significant milestone for Insilico Medicine and the AI driven drug discovery Industry. The milestone is achieved due to the contribution of both the capabilities of our proprietary generative AI platform and the efforts of our multidisciplinary R&D team. We will continue to fully commit to provide breakthrough solutions for the benefit of the patients globally." Following the positive results from this Phase IIa trial, Insilico Medicine will engage regulatory authorities to discuss the design of a Phase IIb study. The company aims to explore extended treatment durations and larger patient cohorts to further investigate ISM001-055's therapeutic potential in IPF. About ISM001-055 and TNIK ISM001-055 is a potentially first-in-class small molecule targeting TNIK utilizing generative AI. In IPF, the activation of TNIK drives pathological fibrosis in the lungs, contributing to the progressive decline in lung function. By inhibiting TNIK, ISM001-055 aims to halt or reverse fibrotic processes, offering a disease-modifying treatment for patients with IPF. In February 2023, ISM001-055 received Orphan Drug Designation from the FDA for treating Idiopathic Pulmonary Fibrosis. About the Phase IIa Study The double-blind, placebo-controlled Phase IIa clinical trial (NCT05938920) evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12-week oral ISM001-055 dosage in 71 subjects with IPF. Patients from 21 sites were randomized into four parallel cohorts: 30mg QD, 30mg BID, 60mg QD, and placebo. Preliminary results from the study show ISM001-055 demonstrated a good safety profile and dose-response trend in lung function in IPF patients. About Idiopathic Pulmonary Fibrosis (IPF) Idiopathic Pulmonary Fibrosis (IPF) is a chronic, scarring lung disease characterized by a progressive and irreversible decline in lung function. Affecting approximately 5 million people worldwide, IPF carries a poor prognosis, with a median survival of 3 to 4 years. Current treatments, including antifibrotic drugs, can slow disease progression but do not stop or reverse it, leaving a significant unmet need for more effective, disease-modifying therapies. IPF is an age-related disease, with the average age of onset typically between 60 and 70 years, and it is most commonly diagnosed in older adults. The disease is rare in individuals under the age of 50. About Insilico Medicine Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to assist novel target discovery and the generation of novel molecular structures. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
Transforming library discovery with Academic AI that provides users a new and easy way to find trusted content LONDON, Sept. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today launched Primo™ Research Assistant. Developed in collaboration with partners from the library community, the new generative AI-powered library discovery solution offers a seamless experience for students and researchers. It provides immediate answers to natural language queries and offers expansive visibility into sources and references. Yariv Kursh, Senior Vice President at Ex Libris™, part of Clarivate™ said: "Primo Research Assistant harnesses responsible academic AI to ensure that students and researchers have access to reliable and trustworthy sources, helping to nurture their curiosity and confidence to push the boundaries of knowledge. By partnering with the community, Clarivate is committed to responsibly applying AI, identifying where AI brings most value and developing best practices." Primo Research Assistant, part of Primo Discovery solution, is built based on a Retrieval Augmented Generation (RAG) architecture and grounded in the Ex Libris Central Discovery Index (CDI), which contains over 5 billion records from thousands of publishers, aggregators and repositories. Key features include: Semantic search and natural language queries: Users can interact with the system using everyday language, making the search process more intuitive. AI-powered answers with references to sources used: The tool provides immediate answers based on the top five abstracts, with links to the full text and the complete result list. Search suggestions: The assistant offers suggestions to help users expand their topics and delve deeper into their research. Non-English query support: Users can ask questions and receive answers in multiple non-English languages. To ensure the product was designed to fit the needs of librarians and their end users, the product was created in close partnership with development partners. The Primo Research Assistant beta program began in June 2024 and featured 18 institutions across 10 different countries/regions. The group of beta testers includes representatives from various cultural and language backgrounds and reflects the diversity of the global academic community. Summon Research Assistant, first announced in June 2024, will launch in Q1 2025. Notes to the editors: Primo Research Assistant is powered by the Clarivate Academic AI Platform, a technology backbone enabling accelerated and consistent deployment of AI capabilities across our portfolio of solutions. All Clarivate AI tools have been responsibly developed in line with the Clarivate AI Principles. This year Clarivate launched the Academia AI Advisory Council, a group committed to fostering a collaborative environment where diverse voices can contribute to the responsible advancement of AI in academia. About ClarivateClarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com Media Contact:Helen Chung-Kesl, Manager, External Communications, Academia & Governmentnewsroom@clarivate.com
Singapore tech workers could reclaim up to 14 hours a week with AI, according to new research SINGAPORE, Sept. 17, 2024 /PRNewswire/ -- ServiceNow (NYSE: NOW), the AI platform for business transformation, today announced a new National Academic Partnership with Republic Polytechnic - the youngest of Singapore's five polytechnics - to provide hundreds of early in career and lifelong learners further access to dynamic and emerging AI and cloud computing roles, supporting the Government's Smart Nation agenda. The news comes as ServiceNow launches its inaugural National Skills research, with Pearson, finding that 15 percent of the new jobs created in Singapore will need people with AI and emerging technologies skills. 361,000 new jobs will arrive in Singapore by 2028 – more than 55,000 in technology specific roles. The ICT, Financial Services, Healthcare, Manufacturing and Professional Services industries will experience the greatest national jobs boost. The research also found that jobs in Singapore will benefit from the biggest time savings by using AI at work, compared to other countries globally. "Jobs in Singapore can look to save up to 14 hours a week, with local based roles such as system administrators, developers, business process analysts, architects and implementation consultants all set to receive a greater time boost when compared to equivalent jobs overseas*said Wee Luen Chia, Managing Director and Group Vice President, ServiceNow Asia. "Everyone can find valuable time savings by putting AI to work, every day. The national productivity gains this will deliver to business, government agencies and the economy is unparalleled. Not to mention the freedom this delivers to people to focus on innovating, growing business and furthering their skills." ServiceNow has trained 1,900 Singaporeans on the company's AI platform within the last 12 months, with more than 600 free courses and 18-job related certification paths available. Innovative Training Program for In-Demand Digital Roles Republic Polytechnic and ServiceNow are launching their first collaborative course in October, through the Diploma in Enterprise Cloud Computing & Management and Diploma in Information Technology. These programs will equip students with the skills and credentials to pursue high-demand careers in fields such as development, digital project management and business digitalisation. The course also connects students to ServiceNow's jobs for these students to access meaningful digital careers with many of the world's leading enterprises within Singapore and across the globe. "As we embrace Singapore's Smart Nation vision, we are excited to collaborate with world-class AI partners like ServiceNow to offer accessible, high-quality, and industry-recognised skills. Through this collaboration, we aim to equip Singaporeans with job-ready skills that align with in-demand roles across the nation. Our courses will open doors for students to access different tech career opportunities across various industries, laying a strong foundation for a successful digital career," said Wai Ling Wong, Director, School of Infocomm, Republic Polytechnic. This partnership builds on ServiceNow's existing skilling commitments with customers, partners and government agencies, including NTUC LearningHub, VITAL Shared Services, Synapxe – Singapore's HealthTech agency, GovTech, Accenture, Fujitsu, Enable - a Fujitsu company, NCS and Tata Consultancy Services, to train employees or skill individuals on ServiceNow's Platform. Local industries to thrive in the AI revolution As AI adoption accelerates, Singapore's labour market will continue to evolve. ServiceNow and Pearson's research reveals that jobs growth within the next five years is expected to be greatest across Singapore's most strategic industries that can expand Singapore's pan-Asia footprint. This projected job growth includes: 33,400 in Telecommunications, Media and Technology 29,300 in Financial Services 15,600 in Healthcare 10,900 in Manufacturing – marking an incredible turnaround for a sector that suffered decline in the workforce in the past 3,900 in Professional Services 300 in Travel Technology careers are now pervasive and cross-industry; ServiceNow expects careers to create 55,000 new roles in Singapore. Jobs like computer and information systems managers, software application developers, and data analysts are expected to see significant growth. Meanwhile, more than 2,200 new technical project managers will be required by companies who are investing in new technologies and systems upgrades, necessitating expertise in project management. 1,500 new application developers will play a vital role in strengthening Singapore's digital core and delivering new services to Singapore citizens. Local talent available for interview: From the age of seven, Vivek Anand has been fascinated by skilling up on computers, starting his career as a Developer, moving into a consultant role and now leading a growing team as a 32-year-old Principal Consultant at Fujitsu. Vivek completed two courses with ServiceNow to sharpen his expertise in emerging technology areas and build confidence to inform business leaders of the value from digital transformation. Vivek completed his first course in 2022 and the second in January 2024 – which have increased salary potential and, more importantly in his words, unlock future career opportunities as part of his journey of lifelong learning. Vivek's philosophy, "When you think of caring for your career, it's similar to how you seed a tree to grow and bear fruits. My career has been a constant, fulfilling process of lifelong learning and continuous growth." On using AI at work to save time, Vivek said, "I save on average 25 minutes each time I use AI, when I receive a customer request – I can auto-populate information based on the customers' specific scenario, quickly solve for issues by quick access to specific data to solve problems and leverage genAI to help with customer responses." Speaking about his most recent upskilling course, he added, "With my company, Fujitsu, investing in additional skilling programs with ServiceNow, I was able to travel overseas and spend a week in-person with 30 brilliant, like-minded people spearheading their organisation's digital journeys. Together, we learnt complex problem-solving skills, leveraging our foundation in analytics to develop and deliver better digital services to end-users and consumers." * Includes USA, Canada, Germany, India, UK, Australia, and Japan. Comparisons based on maximum tech adoption within IT organizations. About ServiceNow ServiceNow (NYSE: NOW) is putting AI to work for people. We move with the pace of innovation to help customers transform organizations across every industry while upholding a trustworthy, human centered approach to deploying our products and services at scale. Our AI platform for business transformation connects people, processes, data, and devices to increase productivity and maximize business outcomes. For more information, visit: www.servicenow.com. © 2024 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated. http://www.servicenow.com Research Methodology: Faethm by Pearson's Labour Market Insights (LMI) modelling predicts how jobs and industries will change over the next 1 to 15 years, considering the impact of emerging technologies and economic trends, assuming moderate technology adoption and expected future economic trends, including population growth. For Singapore, the baseline of the country's labour market is sourced from multiple Ministry of Manpower files, including labour force survey data; economic growth projections are from the International Monetary Fund. By analyzing current time spent on tasks within jobs, the model identifies how emerging technologies can assist or complete these tasks, allowing humans to focus on higher value tasks. Each of the 80,000 tasks in Pearson's ontology is assigned the most likely emerging technology to impact it, with the degree of impact varying by role, industry, and country. Combining these factors, the model provides insights into the shift at the task, job, and industry levels, offering a comprehensive view of the economy.
The move comes as Corti doubles down on its mission to transform overburdened healthcare systems with accessible and trustworthy AI NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Corti, the global AI engine designed for healthcare, is bolstering its leadership team with the addition of three more senior executives. The strategic move furthers the company's mission of helping billions of people benefit from low risk, high quality care through its safe and effective Generative AI, woven into the fabric of every patient interaction around the world. Following a period of rapid growth for the business - which had processed more than 100 million patient interactions - Corti is now welcoming new talent from some of the world's biggest organisations to help continue its expansion. Chad Compton joins Corti as Chief Revenue Officer from Microsoft's leadership team. Prior to Microsoft, Chad was a key executive at Nuance, which was acquired by Microsoft in 2022 for $19.7 billion. At Nuance, he oversaw one of the world's most successful healthcare partnership sales teams, generating hundreds of millions of dollars in revenue. In his new role at Corti, Chad will leverage his extensive experience to drive growth across the global market. Frederik Brabant, MD will step into the role of Chief Medical Strategy Officer. Previously, Frederik served as the chief medical information officer and VP of international healthcare partnerships at Microsoft Nuance. With nearly a decade of leadership experience at Nuance, Frederik played a pivotal role in driving the success of flagship products such as Dragon Dictation and leading global partnership initiatives worth over millions. His role at Corti will be instrumental in shaping the company's medical strategy and expanding its global footprint. Yvonne Kirsch is Corti's new VP Partnerships, North America, coming from Philips Speech, where she was running the North American Unit. Yvonne's experience in building strategic partnerships and driving business growth will power Corti's next chapter in the region, where Corti is on track to process more than 100 million patient interactions annually by 2025. These three new additions to the Corti team builds on a series of other recent hires from Microsoft Nuance and Philips Speech, including Milko Jovanoski, now VP of partnerships for Europe, and Robert Lamprell, UK commercial director, who previously held positions as international marketing director and senior account director at Microsoft Nuance, respectively. Last week, Mikaël Grynszpan also joined the Corti team from Philips Speech as Director of Sales in France, following in the footsteps of Yvonne Kirsch and Corti's CPO, Florian Schwieker, who also made the move from Philips Speech to Corti. Speaking about the new hires, Andreas Cleve, co-founder and CEO of Corti, said: "These critical hires mark a significant milestone for Corti as we continue to scale our impact across healthcare. When top commercial talent moves from such major companies to the promising new incumbent, it marks the start of a new era. Welcoming such unparalleled expertise to the team will be invaluable as we continue to innovate and expand our global reach, clearing the path for billions of patients around the world to enjoy low risk, high quality care." Corti is transforming healthcare by integrating advanced, purpose-built AI into every patient interaction. Its AI seamlessly integrates into virtually any platform, and unlike other co-pilots, it actively supports healthcare professionals by providing real-time prompts, enhancing decision-making throughout their time with patients. It also automates and enhances workflows by removing the need for time-consuming, manual note taking and medical coding - significantly reducing administrative burdens and minimising errors by up to 40 percent. Setting it apart from other AI models built on open-source data, Corti's platform is backed by eight years of research and uses rigorously verified healthcare data, making it the most trustworthy AI support tool available. Processing over 100 million patient interactions every year, Corti is proving to be an indispensable, global asset in delivering high-quality, personalised care. Chad Compton, Chief Revenue Officer at Corti, added: "I'm thrilled to join Corti at such a pivotal moment in the future of healthcare. We're already powering millions of patient interactions every year, and this is just the beginning. Corti is redefining how AI can enhance every corner of healthcare by delivering trusted, real-time support in every patient encounter. Our mission to expand Corti's high-quality AI technology to more healthcare providers worldwide addresses an urgent need, and I am excited to be a part of driving this change." Frederik Brabant, Chief Medical Strategy Officer at Corti, said: "After years of treating individual patients, I realised I could improve the lives of millions if I scaled my efforts beyond the bedside. By reducing administrative burden through safe and effective AI, Corti is relieving healthcare professionals of the immense pressure I once experienced as a physician. I'm looking forward to being part of a team allowing healthcare professionals like me to focus on what truly matters - caring for patients." Yvonne Kirsch, Corti's VP Partnerships North America, said: "Joining Corti in North America amid our exponential growth in the US has been momentous. More providers are seeing the immense potential of Corti's AI - not just for their bottom line, but for easing burnout among overburdened healthcare professionals. Feedback has been overwhelmingly positive, and I'm excited to bring on more strategic partners to extend this technology to thousands more who need it." For more information, please visit: www.corti.ai About Corti Founded in 2016 by Lars Maaløe and Andreas Cleve, Corti is a healthcare AI research company dedicated to developing a safe and effective Generative AI platform tailored to healthcare's unique needs. Having learned from more than 100 million patient interactions, Corti's AI minimizes paperwork and errors across the patient journey, offering expert guidance and support. Corti's AI not only takes notes but also quality assures, journals, codes, nudges, prompts, and documents every patient interaction. This reduces the margin for error by up to 40 percent and administrative time by up to 80 percent. With significant research findings in speech processing, dialectic challenges, medical coding, and language understanding, Corti's artificial intelligence enhances real-time consultations across the entire patient journey across the United States and Europe. Press ContactInkhouse for Corticorti@inkhouse.com
A12 藝術空間
AI Platform
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
